SCHEMBL6994829

SCHEMBL6994829

Cc1cccc2c3c(sc12)Nc1ccccc1NC3=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 4/20 0.40
POLB P06746 2/20 0.38
FLT3 P36888 1/20 0.38
ERBB2 P04626 1/20 0.37
TTR P02766 1/20 0.36
ACVR1 Q04771 3/20 0.36
LRRK2 Q5S007 2/20 0.36
CDK5 Q00535 2/20 0.36
ROS1 P08922 1/20 0.36
KDR P35968 2/20 0.35
PBRM1 Q86U86 1/20 0.35
PDPK1 O15530 1/20 0.35
PDGFRA P16234 2/20 0.35
LTK P29376 2/20 0.35
DYRK1B Q9Y463 2/20 0.35
FER P16591 1/20 0.35
CDK8 P49336 1/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
PARP1 P09874 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6991775 0.77 POLB (0.40) RETPOLBFLT3ERBB2TTR
SCHEMBL6995596 0.76 MAPT (0.49) RETPOLBACVR1LRRK2CDK5
SCHEMBL6992029 0.72 ACVR1 (0.48) POLBACVR1LRRK2CDK5ROS1
SCHEMBL6998771 0.72 CDK5 (0.48) POLBACVR1LRRK2CDK5ROS1
SCHEMBL6998420 0.70 CSNK1G1 (0.50) POLBACVR1LRRK2CDK5ROS1
SCHEMBL6994996 0.70 CSNK1G1 (0.50) POLBACVR1LRRK2CDK5ROS1
SCHEMBL6994826 0.68 CHEK1 (0.47) POLBACVR1LRRK2CDK5KDR
SCHEMBL6993147 0.67 CDK4 (0.43) LRRK2MEN1KMT2AMAPTTDP1
SCHEMBL6997151 0.67 CCNE2 (0.40) POLBACVR1LRRK2KDRPDGFRA
SCHEMBL6992014 0.66 CHEK1 (0.51) POLBLRRK2MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1016664-B1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI PHARMA CORP (JP) 2003-07-02 EP claimed
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2002-04-11 US claimed
US-6271225-B1 PSYCHOLOGICAL DISORDERS WELFIDE CORPORATION (JP) 2001-08-07 US claimed
EP-1016664-A1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2000-07-05 EP claimed
EP-1016664-B1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI PHARMA CORP (JP) 2003-07-02 EP disclosed
US-6455521-B1 PSYCHOLOGICAL DISORDERS; SIDE EFFECT REDUCTION MITSUBISHI PHARMA CORPORATION (JP) 2002-09-24 US disclosed
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2002-04-11 US disclosed
US-6271225-B1 PSYCHOLOGICAL DISORDERS WELFIDE CORPORATION (JP) 2001-08-07 US disclosed
EP-1016664-A1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2000-07-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof ACIN1, ACHE, TPMT RET 3432/4885POLB 1763/4885FLT3 4239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.